Hims & Hers shares jumped nearly 50% in premarket trade on Monday after a report it has ended a dispute with Novo Nordisk by striking a partnership with the Danish drug giant.
FlashNews:
Why a father of five is telling Judy Blume’s revealing life story
Ozempic maker Novo Nordisk gets another downgrade. The end’s in sight for its duopoly status, says TD Cowen.
ROA and and wander Unveil Their Second Collaborative Collection
Hyperliquid’s tokenized futures hit $1.2B as traders bet on oil, stocks
The ‘big brother’ helping Arteta’s Arsenal ‘over the line’
Kaine: Trump calling Iran war an ‘excursion’ is ‘deeply disrespectful’ to service members
The Best Things to Do in Rome Are Some of the Eternal City’s Oldest
Tomás Saraceno and Indigenous communities build art complex in Argentine salt flats
CricketOps Launches Operating Platform for the Growing Insect Protein Farming Industry
CricketOps Launches Operating Platform for the Growing Insect Protein Farming Industry
CricketOps Launches Operating Platform for the Growing Insect Protein Farming Industry
CricketOps Launches Operating Platform for the Growing Insect Protein Farming Industry
CricketOps Launches Operating Platform for the Growing Insect Protein Farming Industry
CricketOps Launches Operating Platform for the Growing Insect Protein Farming Industry
CricketOps Launches Operating Platform for the Growing Insect Protein Farming Industry
CricketOps Launches Operating Platform for the Growing Insect Protein Farming Industry
CricketOps Launches Operating Platform for the Growing Insect Protein Farming Industry
CricketOps Launches Operating Platform for the Growing Insect Protein Farming Industry
CricketOps Launches Operating Platform for the Growing Insect Protein Farming Industry
Home » Hims & Hers stock rockets on reported end to Novo Nordisk weight-loss drug dispute